The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee gave the agency a lot to ponder as it considers whether to approve Mallinckrodt plc's new immediate-release (IR) formulation of oxycodone and determines if it warrants abuse-deterrent labeling.